Paliperidon Sandoz (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidon Sandoz, is a atypical antipsychotic presented as a long‑acting injectable formulation for intramuscular use. It is indicated for the treatment of schizophrenia and related psychotic disorders in adult patients. GNH USA supplies Paliperidon Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone palmitate is used in the management of schizophrenia, a chronic psychotic disorder, and related conditions. - Schizophrenia: reduces risk of relapse and stabilises symptoms in adults. - Schizoaffective disorder (depressive type): controls psychotic and mood symptoms. - Maintenance therapy: provides once‑monthly dosing to improve treatment adherence.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Weight gain: increase in body weight over time. - Akathisia: restlessness or inner tension. - Somnolence: feeling unusually sleepy. - Headache: mild to moderate head pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Tardive dyskinesia: involuntary, repetitive movements. - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Hyperglycaemia: elevated blood glucose levels. - Orthostatic hypotension: sudden drop in blood pressure upon standing. - Seizures: convulsive episodes, especially in predisposed individuals. - Agranulocytosis: severe reduction in white blood cells.

Before initiating therapy, clinicians should consider several safety aspects. - Cardiovascular assessment: monitor blood pressure and heart rate regularly. - Metabolic screening: check fasting glucose and lipid profile. - Seizure history: use cautiously in patients with prior seizures. - Hypersensitivity: avoid in individuals with known allergy to paliperidone or excipients. - Pregnancy and lactation: discuss potential risks with the prescriber. - Store at room temperature: keep in the original container, protect from moisture and light.

Paliperidone palmitate may interact with several drug classes. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase paliperidone exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce paliperidone levels. - QT‑prolonging agents (e.g., quinidine): additive risk of cardiac arrhythmia. Moderate Interactions (Monitor Closely):\n- Antihypertensives: may enhance orthostatic hypotension. - Anticholinergic drugs: may mask extrapyramidal symptoms. - Moderate CYP3A4 inducers (e.g., carbamazepine): may lower drug exposure.